Technology
Health
Biotechnology

Myriad Genetics

$33.16
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.06 (0.18%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell MYGN and other stocks, options, ETFs, and crypto commission-free!

About

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through Diagnostics and Other segments. Read More The Diagnostics segment engages in the provision of testing and collaborative development of testing that is designed to asses a risk of developing a disease later in life of an individual. The Other segmeng provides products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake, UT.

Employees
2,400
Headquarters
Salt Lake City, Utah
Founded
1991
Market Cap
2.42B
Price-Earnings Ratio
91.03
Dividend Yield
Average Volume
850.49K
High Today
$33.34
Low Today
$32.61
Open Price
$33.11
Volume
326.37K
52 Week High
$50.44
52 Week Low
$26.80

Collections

Technology
Health
Biotechnology
Advertising and Marketing
Medical
Pharmaceutical
Research And Development
Finance

News

Markets InsiderMar 21

Myriad to Present 18 Studies at the 2019 Annual Clinical Genetics Meeting

SALT LAKE CITY, March 21, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that its Myriad Women’s Health business unit will present data from 18 studies at the 2019 Annual Clinical Genetics Meeting (ACMG) being held April 2-6, 2019 in Seattle. “We are excited to be presenting new data across multiple genetic tests at ACMG and to highlight our progress in advancing precision medicine for women,” said James Goldberg, M.D., board certified mate...

32
Yahoo FinanceMar 18

Myriad's myPath Melanoma Test Awarded Medicare Coverage

Myriad Genetics, Inc. MYGN recently announced the issuance of a final local coverage determination (LCD) by the Medicare Administrative Contractor Palmetto GBA MolDx for the myPath Melanoma test. Notably, myPath Melanoma is a clinically confirmed test to be used as an adjunct to histopathology. The test holds importance when histopathology alone cannot conclusively differentiate between a benign nevus and a malignant melanoma. Moreover, the myPath Melanoma test examines 23 genes and has demonstrated accura...

33
The Motley FoolMar 11

Here's Why Genetic Testing Stocks Rose as Much as 42.9% in February

What happened February was a great month for genetic testing stocks. Shares of Invitae (NYSE:NVTA) paced the pack with a monthly gain of 42.9%, according to data provided by S&P Global Market Intelligence. That was followed by NeoGenomics (NASDAQ:NEO) and Myriad Genetics (NASDAQ:MYGN), which rose 17.9% and 10.1%, respectively. Each stock soared on the heels of impressive quarterly operating results. The industry has long been a source of eye-popping growth, but is now harboring multiple profitable busines...

1,032

Earnings

$0.21
$0.28
$0.36
$0.43
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.